Literature DB >> 20393476

Interpretation of quality-of-life scores.

Mary-Margaret Chren1.   

Abstract

Patients' reports of their experience with illness are a key health outcome, but scores that measure these reports can be difficult to interpret. Skindex-29 measures skin-related quality of life reliably and validly. In this issue, Prinsen and colleagues compare patients' responses to "anchor" questions with their Skindex scores to derive clinically meaningful scores for the subscales of Skindex-29. The cutoff scores identify patients whose skin diseases severely affect their quality of life.

Entities:  

Mesh:

Year:  2010        PMID: 20393476      PMCID: PMC3150524          DOI: 10.1038/jid.2010.51

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  12 in total

1.  Measurement of vital signs for skin diseases.

Authors:  Mary-Margaret Chren
Journal:  J Invest Dermatol       Date:  2005-10       Impact factor: 8.551

2.  Estimation of the Youden Index and its associated cutoff point.

Authors:  Ronen Fluss; David Faraggi; Benjamin Reiser
Journal:  Biom J       Date:  2005-08       Impact factor: 2.207

Review 3.  Critical review of generic and dermatology-specific health-related quality of life instruments.

Authors:  Hilde Both; Marie-Louise Essink-Bot; Jan Busschbach; Tamar Nijsten
Journal:  J Invest Dermatol       Date:  2007-11-08       Impact factor: 8.551

4.  Categorization of Skindex-29 scores using mixture analysis.

Authors:  Tamar Nijsten; Francesca Sampogna; Damiano Abeni
Journal:  Dermatology       Date:  2008-12-06       Impact factor: 5.366

5.  It's all about patients.

Authors:  Paul R Bergstresser
Journal:  J Invest Dermatol       Date:  2010-01       Impact factor: 8.551

6.  Natural history of prostatism: urinary flow rates in a community-based study.

Authors:  C J Girman; L A Panser; C G Chute; J E Oesterling; D M Barrett; C C Chen; H M Arrighi; H A Guess; M M Lieber
Journal:  J Urol       Date:  1993-09       Impact factor: 7.450

Review 7.  The significance of treatment effects: the clinical perspective.

Authors:  R A Deyo; D L Patrick
Journal:  Med Care       Date:  1995-04       Impact factor: 2.983

Review 8.  Interpretation of quality of life changes.

Authors:  E Lydick; R S Epstein
Journal:  Qual Life Res       Date:  1993-06       Impact factor: 4.147

Review 9.  Reporting and interpretation of SF-36 outcomes in randomised trials: systematic review.

Authors:  Despina G Contopoulos-Ioannidis; Anastasia Karvouni; Ioanna Kouri; John P A Ioannidis
Journal:  BMJ       Date:  2009-01-12

10.  Health-related quality of life assessment in dermatology: interpretation of Skindex-29 scores using patient-based anchors.

Authors:  Cecilia A C Prinsen; Robert Lindeboom; Mirjam A G Sprangers; Catharina M Legierse; John de Korte
Journal:  J Invest Dermatol       Date:  2009-12-24       Impact factor: 8.551

View more
  4 in total

Review 1.  The Skindex instruments to measure the effects of skin disease on quality of life.

Authors:  Mary-Margaret Chren
Journal:  Dermatol Clin       Date:  2011-12-20       Impact factor: 3.478

2.  The Impact of Neurofibromatosis Type 1 on the Health and Wellbeing of Australian Adults.

Authors:  Hilda A Crawford; Belinda Barton; Meredith J Wilson; Yemima Berman; Valerie J McKelvey-Martin; Patrick J Morrison; Kathryn N North
Journal:  J Genet Couns       Date:  2015-04-19       Impact factor: 2.537

3.  Effect of store and forward teledermatology on quality of life: a randomized controlled trial.

Authors:  John D Whited; Erin M Warshaw; Karen E Edison; Kush Kapur; Lizy Thottapurathu; Srihari Raju; Bethany Cook; Holly Engasser; Samantha Pullen; Patricia Parks; Tom Sindowski; Danuta Motyka; Rodney Brown; Thomas E Moritz; Santanu K Datta; Mary-Margaret Chren; Lucinda Marty; Domenic J Reda
Journal:  JAMA Dermatol       Date:  2013-05       Impact factor: 10.282

4.  A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor-Induced Skin Toxicities.

Authors:  Young Saing Kim; Jun Ho Ji; Sung Yong Oh; Suee Lee; Seok Jae Huh; Ji Hyun Lee; Ki-Hoon Song; Choon Hee Son; Mee Sook Roh; Gyeong Won Lee; Jeeyun Lee; Seung Tae Kim; Chan Kyu Kim; Joung Soon Jang; In Gyu Hwang; Hee Kyung Ahn; Lee Chun Park; So Yeon Oh; Seong-Geun Kim; Sang-Cheol Lee; Do-Hyoung Lim; Soon Il Lee; Jung Hun Kang
Journal:  Oncologist       Date:  2019-09-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.